CD274 and esophageal squamous cell carcinoma: The study findings are in line with a previous meta-analysis involving 5 phase III trials [30] and support the approval of anti-PD-1/PD-L1 therapy plus platinum-based chemotherapy as first-line systemic therapy for all patients with advanced ESCC by many health-related regulatory authorities worldwide.